3 Must-Buy Stocks for June 2025 – Top Analysts’ Highest-Conviction Picks

Wall Street’s sharpest minds are doubling down on these equities—just don’t expect your broker to mention them until after their hedge fund buddies front-run the trade.

The Contrarian Power Play

While retail investors chase meme stocks, institutions are quietly accumulating positions in these overlooked cash-flow machines. One boasts a 30% free-cash-flow yield—if you believe the adjusted EBITDA fairy tales.

The AI Arms Race Winner

Nvidia’s little-known supplier is crushing guidance quarter after quarter. Their proprietary chip-stacking tech makes TSMC’s nodes look like antique lithography.

The Regulatory Arbitrage

This pharma play’s patent cliff is really a revenue springboard—their ‘generic’ biologics face exactly zero competition until 2031. Thank you, captured FDA.

Remember: These ‘top picks’ only work if you get in before the analysts’ 11am CNBC appearances. Past performance indicates they usually leak to preferred clients around 9:45am.

Confident Investing Starts Here:

• Easily unpack a company''s performance with TipRanks'' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks'' Smart Value Newsletter

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

(MRUS) – Merus is a clinical-stage biotechnology company that develops human bispecific and trispecific antibody therapies for cancer. Yesterday, Citi analyst Yigal Nochomovitz maintained a Buy rating on the stock and increased the price target to $102 from $97 per share. In the last three months, all five Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 80.93%.

(ACMR) – This is a U.S.-based semiconductor equipment company that develops advanced wafer cleaning and front-end process tools. Yesterday, Benchmark Co. analyst Mark Miller maintained a Buy rating on the stock with a price target of $38 per share. In the last three months, all three Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 50.87%.

(NVDA) – This is a semiconductor company best known for its graphics processing units (GPUs) and its growing dominance in AI and data center markets. Yesterday,William Blair analyst Sebastien Naji maintained a Buy rating on the stock. Interestingly, 31 out of the 34 Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 22.09%. 

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. 

See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks’ Top Wall Street Analysts page. 

Disclosure